Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies

from Oncology Learning Network · host HMP Global

Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)."

Episode metadata supplied by the publisher feed · Published Dec 17, 2020

Embed this episode

Attribution link and audio player

Ready to play

Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies

0:00 7:51

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 7 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on December 17, 2020.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!